Loading company…
Matridx is a Hangzhou company focused on molecular diagnosis of infectious diseases using CRISPR, NGS and AI-based analysis.
Established in 2019 and based in Hangzhou, China, Matridx develops molecular diagnosis solutions for infectious diseases using CRISPR/Cas gene editing and high-throughput sequencing. Its products include the Pathogen Macro Gene Banker, an mNGS assay kit and a SARS-CoV-2 nucleic acid detection solution. The company has acquired more than 100 patents. In December 2023 it closed Series C+ funding from Zhejiang Yuhang Industrial Transformation & Upgrading Investment and Jiujiang Kuntai Equity Investment Fund Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in